Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

unknown125%
completed125%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
completedphase_3

Molecular Profiling of Advanced Soft-tissue Sarcomas

NCT03784014
unknown

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04507503
recruitingphase_2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176
recruitingphase_1

AB122 Platform Study

NCT04999761

Clinical Trials (4)

Showing 4 of 4 trials
NCT03784014Phase 3

Molecular Profiling of Advanced Soft-tissue Sarcomas

Completed
NCT04507503

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Unknown
NCT05727176Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Recruiting
NCT04999761Phase 1

AB122 Platform Study

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4